Patents Represented by Attorney, Agent or Law Firm A. Dean Olson
  • Process for making .beta.-O-cellobiosyl steroid derivatives and trimethyl silyl steroid intermediates used therein
    Patent number: 5563259
    Abstract: A process for the synthesis of peracyl-1-O-steroidal-.beta.-cellobiosides that provides excellent .beta.-anomeric selectivity without the use of a metal salt promoter. The process comprises reacting heptaacyl-.beta.-D-cellobiosyl-1-fluoride and a trisubstituted silyl-3-O-steroid, wherein the steroid is tigogenin, hecogenin, 11-ketotigogenin or diosgenin in the absence of a metal salt under suitable conditions.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: October 8, 1996
    Assignee: Pfizer Inc.
    Inventors: Kathleen D. Goggin, John F. Lambert, Stanley W. Walinsky
  • Method of producing porous delivery devices
    Patent number: 5529789
    Abstract: An efficient method for making high strength, highly porous, fast dissolving delivery devices. The method comprises mixing a formulation comprising menthol, a water-soluble, menthol-soluble polymer, and an active agent at a temperature such that the menthol is substantially molten. The formulation is disposed in a mold, solidified and the menthol is sublimed from the solidified molded formulation. Preferably, the solidification occurs at a temperature sufficient to provide a substantially amorphous menthol structure.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: June 25, 1996
    Assignee: Pfizer, Inc.
    Inventor: Julian B. Lo
  • Method for making steroidal peracyl glycosides
    Patent number: 5530107
    Abstract: Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypocholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting .alpha.-cellobiosyl bromide heptaalkanoate and .beta.-tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl .beta.-O-cellobioside heptaalkanoate. The analogous preparations of hecogenin .beta.-O-cellobioside heptaalkanoate, 11-ketotigogenin .beta.-O-cellobioside heptaalkanoate, and diosgenin .beta.-O-cellobioside heptaalkanoate are also disclosed. The process provides both high .beta.-anomeric selectivity and high yields.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: June 25, 1996
    Assignee: Pfizer Inc.
    Inventors: Douglas J. M. Allan, Frank R. Busch, John F. Lambert, Russell J. Shine, Stanley W. Walinsky
  • Dispensing device powered by hydrogel
    Patent number: 5516527
    Abstract: This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by hydrogel. This invention also relates to the controlled delivery of one or more beneficial agents to an aqueous environment of use through the use of such hydrogel powered dispensing devices. Also disclosed are methods for the controlled delivery of one or more beneficial agents to an aqueous environment of use which comprises administering to or otherwise placing the devices of this invention in the environment of use.
    Type: Grant
    Filed: October 9, 1992
    Date of Patent: May 14, 1996
    Assignee: Pfizer Inc.
    Inventor: William J. Curatolo
  • Porous shaped delivery devices and method of producing thereof
    Patent number: 5516530
    Abstract: High strength, high porosity delivery devices have a shaped surface and disintegrate quickly in an aqueous medium. The devices can be prepared by disposing a formulation in a die to form a frozen predevice. A second die is contacted with the frozen formulation surface at a pressure and temperature for a time sufficient to locally momentarily liquify and shape the device surface. The shaping is followed by lyophilization.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: May 14, 1996
    Assignee: Pfizer Inc.
    Inventors: Julian B. Lo, Gary G. Mackay, Michael J. Puz
  • Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
    Patent number: 5475116
    Abstract: This invention relates to certain azabicyclo hexane intermediates and processes for making and using the azabicyclo hexane intermediates. The intermediates are useful in the synthesis of quinolone antibacterial agents.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: December 12, 1995
    Assignee: Pfizer Inc.
    Inventors: Katherine E. Brighty, Tamim F. Braish
  • Dihydroxyindanone tyrosine kinase inhibitors
    Patent number: 5457237
    Abstract: Certain dihydroxyindanone compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis).
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: October 10, 1995
    Assignee: Pfizer Inc.
    Inventor: Robert L. Dow
  • Pyridine derived agents for cardiovascular diseases
    Patent number: 5457118
    Type: Grant
    Filed: April 20, 1994
    Date of Patent: October 10, 1995
    Assignee: Pfizer Inc.
    Inventors: Roger P. Dickinson, Kevin N. Dack, John Steele
  • Dispensing device containing a hydrophobic medium
    Patent number: 5431921
    Abstract: A device for the controlled delivery of an insoluble or partially aqueous insoluble beneficial agent to an aqueous containing environment. The device comprises a shaped wall that surrounds and defines an internal reservoir. The wall is formed at least in part of a sintered polymer microporous membrane permeable to a beneficial agent-containing hydrophobic medium when the wall is present in the aqueous containing environment. The reservoir contains a mixture of a hydrophilic swellable composition and a beneficial agent-containing hydrophobic medium.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: July 11, 1995
    Assignee: Pfizer Inc
    Inventor: Avinash G. Thombre
  • Process for sultamicillin intermediate
    Patent number: 5399678
    Abstract: A simplified method for making the chloromethyl ester of sulbactam in which the tetraalkylammonium sulbactam salt is not dried and isolated prior to alkylation. The method comprises reacting a tetraalkylammonium salt and a sulbactam salt in an aqueous solution to form an aqueous solution of tetraalkylammonium sulbactam. The tetraalkylammonium sulbactam is extracted into bromochloromethane or iodochloromethane, and water is removed from the organic layer to enhance the formation of the chloromethyl ester of sulbactam. The tetraalkylammonium sulbactam is reacted with bromochloromethane or iodochloromethane in the organic layer to form the chloromethyl ester of sulbactam.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: March 21, 1995
    Assignee: Pfizer Inc.
    Inventors: Dennis M. Godek, Thomas A. Morris
  • PH-triggered osmotic bursting delivery devices
    Patent number: 5358502
    Abstract: An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane. Alternatively the beneficial agent may also function as the osmagent. The semipermeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached to the semipermeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: October 25, 1994
    Assignee: Pfizer Inc
    Inventors: Scott M. Herbig, Kelly L. Smith
  • Imidazopyridine PAF/H.sub.1 antagonists
    Patent number: 5358953
    Abstract: Compounds of formula (1), wherein X is CH or N; Z is CH.dbd.CH or S; A is CH.sub.2 CH.sub.2, CH.dbd.CH, CH(OH)CH.sub.2, or COCH.sub.2 ; B is a direct link or --CH.sub.2 --, --CH(CH.sub.3)-- or --C(CH.sub.3).sub.2 --; or when Z is CH.dbd.CH, B may form a cyclopentane ring fused to the attached benzene ring; Y completes a fused benzo or thienyl ring which is optionally substituted by halo or C.sub.1 -C.sub.4 alkyl; n is 0, 1 or 2; and m is 0 or 1; are antagonists of both PAF and histamine H.sub.1 having utility in the treatment of allergic inflammatory conditions such as allergic rhinitis.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: October 25, 1994
    Assignee: Pfizer Inc.
    Inventors: David Alker, Robert J. Bass, Kelvin Cooper
  • Benzylphosphonic acid tyrosine kinase inhibitors
    Patent number: 5326905
    Abstract: Certain benzylphosphonic acid compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis).
    Type: Grant
    Filed: September 16, 1992
    Date of Patent: July 5, 1994
    Assignee: Pfizer Inc.
    Inventors: Robert L. Dow, Steven W. Goldstein
  • Substituted chromans and their use in the treatment of asthma, arthritis and related diseases
    Patent number: 5298512
    Abstract: Substituted chromans which by inhibiting 5-lipoxygenase enzyme are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction, stroke and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.
    Type: Grant
    Filed: September 30, 1991
    Date of Patent: March 29, 1994
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Anthony Marfat, Hiroko Masamune, Lawrence S. Melvin, Jr.
  • Heterocyclic compounds as aldose reductase inhibitors
    Patent number: 5294635
    Abstract: Certain spirocyclic heterocyclic compounds, and their pharmaceutically-acceptable salts, are inhibitors of the aldose reductase enzyme, and so are useful for the control of diabetic complications.
    Type: Grant
    Filed: September 17, 1992
    Date of Patent: March 15, 1994
    Assignee: Pfizer, Inc.
    Inventors: James F. Eggler, Eric R. Larson
  • Method of treating impotence
    Patent number: 5270323
    Abstract: A method of relieving erectile impotence in a human male. The method comprises administering to the male an erectile impotence relieving amount of a compound selected from the group consisting of U.K. 52,046, Amlodipine, Doxazosin and the pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: March 11, 1993
    Date of Patent: December 14, 1993
    Assignee: Pfizer Inc.
    Inventors: George M. Milne, Jr., Michael G. Wyllie
  • Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma
    Patent number: 5248685
    Abstract: Substituted 1-[3-(heteroarylmethoxy)phenyl]-alkanols and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction, stroke and related disease states in mammals; pharmaceutical compositions thereof; and a method of treatment therewith.
    Type: Grant
    Filed: September 30, 1991
    Date of Patent: September 28, 1993
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Anthony Marfat, Hiroko Masamune, Lawrence S. Melvin, Jr.
  • Ceramic membrane removal tool
    Patent number: 5247727
    Abstract: A tool for removing filter membranes from a filter housing without breaking the membranes. The tool comprises a threaded screw means (27) for pressing the membrane (60) though holes in opposing sides of the housing (48) and a guide means (21) for maintaining the screw means (27 ) in alignment with the holes. The guide means (21) has a threaded hole for receiving the threaded screw means (27) therethrough. The guide means (21) is slidably retained along a beam (3) and disposed between removable fastening means (9, 12) used to clamp the tool to the filter housing (48).
    Type: Grant
    Filed: July 22, 1992
    Date of Patent: September 28, 1993
    Assignee: Pfizer Inc.
    Inventors: John G. Harris, Willard K. Moon
  • Bridged bicyclic imides as anxiolytics and antidepressants
    Patent number: 5242911
    Abstract: A series of bridged bicyclic imide compounds having a 4-(4-[2-pyrimidinyl]-1-piperazinyl)butyl group attached to the imide nitrogen are useful for alleviating the symptoms of anxiety and depression in human subjects.
    Type: Grant
    Filed: May 23, 1989
    Date of Patent: September 7, 1993
    Assignee: Pfizer Inc.
    Inventor: Gene M. Bright
  • Cephalosporin compounds
    Patent number: 5120728
    Abstract: Certain cephalosporin compounds, and their pharmaceutically- accepted salts or in vivo hydrolyzable esters are useful as antibacterial agents.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: June 9, 1992
    Assignee: Pfizer Inc.
    Inventor: Isao Nagakura